Contact Information
Address (Office) E12-4006  
(Lab) N22-3001
Phone (Office) 8822 4991
(Lab) 8822 4218
Fax 8822 2314
PhD in Biomedical Sciences University of Ulster, UK (2003)
BSc (1st Class Hons) in Biotechnology University of Ulster, UK (2000)
NVQ Level 4 (Higher National Diploma) in Management Chartered Management Institute, UK (2007)
2014-present Assistant Professor, Faculty of Health Sciences,
University of Macau
2014-present Choi Kai Yau College (CKYC) Fellow, University of Macau
2013-present Visiting Scientist, Cancer Research UK Cambridge Institute, University of Cambridge, UK
2007-2016 Visiting Research Fellow, School of Pharmacy, Queen’s University Belfast, UK
2011-2014 Senior Research Associate / Fellow, Department of Oncology / Cancer Research UK Cambridge Institute, University of Cambridge, UK
2007-2011 Senior Scientist, Fusion Antibodies Ltd., UK
2004-2007 Knowledge Transfer & Research Scientist, School of Pharmacy, Queen’s University Belfast, UK
Research Interests
After a 1st class BSc (Hons) degree in Biotechnology and a PhD in Biomedical Sciences, Hang Fai awarded a Knowledge Transfer Partnerships Fellowship as a post-doctoral researcher in the UK no. 1 Pharmacy School at the Queen’s University Belfast (QUB), before moving to industry as a senior scientist in the QUB spinout company — Fusion Antibodies Ltd. He then returned to academia as a senior research fellow in the Department of Oncology University of Cambridge, working with Prof Gillian Murphy at the Cancer Research UK Cambridge Institute and bringing together his interests in protease biochemistry research with biologics development (e.g. antibody therapy, peptide-based therapy) to pursue novel therapeutic, prognostic and diagnostic approaches in the treatment of cancer and other diseases. Apart from protease and antibody research, Hang Fai is also a visiting fellow in Prof Chris Shaw’s Natural Drug Discovery group at the School of Pharmacy QUB since 2007 and collaborate with Prof Bryan Fry (University of Queensland, Australia), focuses on proteomic characterization of novel bioactive molecules from sources in nature including amphibian defensive skin secretions, reptile, scorpion and insect venoms for exploiting their therapeutic potential.
Representative Publications
Journal Articles:

  • Wang Q., Lin W., Tang X., Li S., Guo L., Lin Y.*, Kwok H. F.* (2017) The roles of microRNAs in regulating the expression of PD-1/PD-L1 immune checkpoint. International Journal of Molecular Sciences 18(12): 2540.
  • Zhong H., Chen B., Neves H., Xing J., Ye Y., Lin Y., Zhuang G., Zhang S. D., Huang J., Kwok H. F.* (2017) Expression of minichromosome maintenance genes in renal cell carcinoma. Cancer Management and Research 9: 637-647.
  • Wong J. P. C., Wei R., Lyu P., Tong O. L. H., Zhang S. D., Wen Q., Yuen H. F., El-Tanani M., Kwok H. F.* (2017) Clinical and in vitro analysis of Osteopontin as a prognostic indicator and unveil its potential downstream targets in bladder cancer. International Journal of Biological Sciences 13(11): 1373-1386.
  • Ling Y., Chen J., Guo L., Wang C., Tan W., Wen Q., Zhang S. D., Deng G.*, Lin Y.*, Kwok H. F.* (2017) β-defensin 1 expression in HCV infected liver/liver cancer: an important role in protecting HCV progression and liver cancer development. Scientific Reports 7(1): 13404.
  • Ma R., Mahadevappa R., Kwok H. F.* (2017) Venom-based peptide therapy: insights into anti-cancer mechanism. Oncotarget 8(59): 100908-100930.
  • Guo L., Lin Y., Kwok H. F.* (2017) The function and regulation of PD-L1 in immunotherapy. ADMET and DMPK 5(3): 159-172.
  • Mahadevappa R., Ma R., Kwok H. F.* (2017) Venom peptides — Improving specificity for cancer therapy. Trends in Cancer 3(9): 611-614.
  • Koludarov I., Jackson T. N. W., Brouw B., Dobson J., Dashevsky D., Arbuckle K., Clemente C. J., Stockdale E. J., Cochran C., Debono J., Stephens C., Panagides N., Li B., Manchadi M. R., Violette A., Fourmy R., Hendrikx I., Nouwens A., Clements J., Martelli P., Kwok H. F. and Fry B. G. (2017) Enter the Dragon: The Dynamic and Multifunctional Evolution of Anguimorpha Lizard Venoms. Toxins 9(8): 242.
  • Wei R., Wong J.P.C. and Kwok H. F.* (2017) Osteopontin — a promising biomarker for cancer therapy. Journal of Cancer 8(12): 3173-2183.
  • Li L., Guo L., Wang Q., Liu X., Zeng Y., Wen Q., Zhang S., Kwok H. F.* and Lin Y.*, Liu J.* (2017) DAPK1 as an independent prognostic marker in liver cancer. PeerJ 5:e3568.
  • Wong J.P.C., Li B. and Kwok H. F.* (2017) Venom Peptides and Toxins – A Prospective Spearhead in Cancer Treatment. Combinatorial Chemistry High Throughput Screen 20(5): 1-19.
  • Neves H. and Kwok H. F.* (2017) In sickness and in health: The many roles of the minichromosome maintenance proteins. BBA – Reviews on Cancer 1868(1): 295-308.
  • Ye J., Yuen S. M., Murphy G., Xie R.* andKwok H. F.* (2017) Anti-Tumour Effects of a ‘Human & Mouse Cross-Reactive’ Anti-ADAM17 Antibody in a Pancreatic Cancer Model In Vivo. European Journal of Pharmaceutical Sciences pii: S0928-0987(17)30297-X. doi: 10.1016/j.ejps.2017.05.057.
  • Debono J., Dobson J., Casewell N.R., Romilio A., Li B., Kurniawan N., Mardon K., Weisbecker V., Nouwens A., Kwok H. F., Fry B. G. (2017) Coagulating Colubrids: Evolutionary, Pathophysiological and Biodiscovery Implications of Venom Variations between Boomslang (Dispholidus typus) and Twig Snake (Thelotornis mossambicanus). Toxins 9(5): pii: E171.
  • Cipriani V., Debono J., Goldenberg J., Jackson T. N. W., Arbuckle K., Dobson J., Koludarov I., Li B., Hay C., Dunstan N., Allen L., Hendrikx I., Kwok H. F. and Fry B. G. (2017) Correlation between ontogenetic dietary shifts and venom variation in Australian brown snakes (Pseudonaja). Comp Biochem Physiol C Toxicol Pharmacol 197: 53-60.
  • Xie J. Y., Chen P. C., Zhang J. L., Gao Z. S., Neves H., Zhang S. D., Wen Q., Chen W. D., Kwok H. F.* and Lin Y.* (2017) The prognostic significance of DAPK1 in bladder cancer. PLoS One 12(4): e0175290.
  • Mahadevappa R. and Kwok H. F.* (2017) Phytochemicals – A Novel and Prominent Source of Anti-cancer Drugs against Colorectal Cancer. Combinatorial Chemistry High Throughput Screen 20: 1-19.
  • Lyu P., Zhang S. D., Yuen H. F., McCrudden C. M., Wen Q., Chan K. W. and Kwok H. F.* (2017) Identification of TWIST-interacting genes in prostate cancer. Science China Life Sciences 60(4): 386-396.
  • Xiao Y., Yan W., Guo L., Meng C., Li B., Neves H., Chen P., Li L., Huang Y., Kwok H. F.* and Lin Y.* (2017) Digitoxin Synergized with Sorafenib to Inhibit Hepatocelluar Carcinoma Cell Growth and Migration. Molecular Medicine Reports 15(2): 941-947.

  • Li B., McCrudden C. M., Yuen H. F., Xi X., Lyu P., Chan K. W., Zhang S. D. and Kwok H. F.* (2016) CD133 in brain tumor: the prognostic factor. Oncotarget 8(7): 11144-11159.
  • Takayanagi T., Forrester S. J., Kawai T., Obama T., Tsuji T., Elliott K. J., Nuti E., Rossello A., Kwok H. F., Scalia R., Rizzo V. and Eguchi S. (2016)Vascular ADAM17 as a Novel Therapeutic Target in Mediating Cardiovascular Hypertrophy and Perivascular Fibrosis Induced by Angiotensin II. Hypertension 68: 949-955.
  • Shi D., Hou X., Wang L., Gao Y., Wu D., Xi X.*, Zhou M.*, Kwok H. F*., Duan J., Chen T. and Shaw C. (2016) Two Novel Dermaseptin-Like Antimicrobial Peptides with Anticancer Activities from the Skin Secretion of Pachymedusa dacnicolor. Toxins 8(5): 144.
  • Yuen S. M. and Kwok H. F.* (2016) Temporal establishment of neural cell identity in vivo and in vitro. Journal of Tissue Engineering and Regenerative Medicine. doi: 10.1002/term.2158.
  • Botkjaer K. A.*, Kwok H. F*., Terp M. G., Karatt-Vellatt A., Santamaria S., McCafferty J., Andreasen P. A., Itoh Y., Ditzel H. J. and Murphy G.* (2016) Development of specific affinity-matured exosite inhibitor to MT1-MMP that efficiently inhibits tumor cell invasion in vitro and metastasis in vivo. Oncotarget 7(13): 16773-16792.
  • Zhang S. D., McCrudden C. M., Yuen H. F., Leung K. L., Hong W. J. and Kwok H. F.* (2016) The association of TAZ, AXL and CTGF expression with clinicopathological parameters in colon cancer Oncology Letters 11: 1223-1229.

  • Zhang S. D., Leung K. L., McCrudden C. M. and Kwok H. F.* (2015) The prognostic significance of combining VEGFA, FLT1 and KDR mRNA expressions in brain tumors. Journal of Cancer. 6(9): 812-818.
  • Zhang S. D., McCrudden C. M. and Kwok H. F.* (2015) The prognostic significance of combining VEGFa, FLT1 and KDR mRNA expressions in lung cancer. Oncology Letters 10: 1893-1901.
  • Zhao D., Guo L., Neves H., Yuen H. F., Zhang S. D., McCrudden C. M., Wen Q., Zhang J., Zeng Q., Kwok H. F.* and Lin Y.* (2015) The prognostic significance of protein tyrosine phosphatase 4A2 in breast cancer. OncoTargets and Therapy. 8: 1707-1717.
  • Huang Y., Zhang S. D., McCrudden C. M., Chan K. W., Yao L. and Kwok H. F.* (2015) The prognostic significance of PD-L1 in bladder cancer. Oncology Reports. 33: 3075-3084.
  • Zhang S. D., McCrudden C. M., Meng C., Lin Y* and Kwok H. F.* (2015) The significance of combining VEGFa, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab. OncoTargets and Therapy. 8: 835-843.
  • Neves H. and Kwok H. F.* (2015) Recent advances in the field of anti-cancer immunotherapy. BBA Clinical. 3: 280-288.
  • Xi X., Li B., Chen T. and Kwok H. F.* (2015) A Review on Bradykinin-Related Peptides Isolated from Amphibian Skin Secretion. Toxins. 7(3): 951-970.
  • Kwok H .F.*, Zhang S. D., McCrudden C. M., Yuen H. F., Ting K. P., Wen Q., Khoo U.S.* and Chan K. Y. K.* (2015) Prognostic significance of minichromosome maintenance proteins in breast cancer. American Journal of Cancer Research. 5(1): 52-71.

  • Huang Y., Benaich B., Tape C .J., Kwok H. F.* and Murphy G.* (2014) Targeting the sheddase activity of ADAM17 by an anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivation. International Journal of Biological Sciences. 10(7): 702-714.
  • Kwok H. F.*, Botkjaer K. A., Tape C. J., Huang Y., McCafferty J. and Murphy G. (2014) Development of a ‘mouse and human cross-reactive’ affinity-matured exosite inhibitory human antibody specific to TACE (ADAM17) for cancer immunotherapy. PEDS 27(6): 179-190.
  • van’t Wout E. F. A., Dickens J. A., van Schadewijk A., Haq I., Kwok H. F., Ordóñez A., Murphy G., Stolk J., Lomas D. A., Hiemstra P. S. and Marciniak S. J. (2014) Excess ERK signalling promotes inflammatory signalling in primary airway epithelium expressing Z α1-antitrypsin. Human Molecular Genetics 23(4): 292-241.

  • Kwok H. F.* (2013) Antibody research targeting Cathepsin S for cancer therapy. Advances in Bioscience and Biotechnology 4(4A):17-20.
  • Burden R. E., Gormley J. A., Kuehn D., Ward C., Kwok H. F., Gazdoiu M., McClurg A., Jaquin T., Johnston J. A., Scott C. J. and Olwill S. A. (2012) Inhibition of Cathepsin S by Fsn0503 enhances the efficacy of chemotherapy in colorectal carcinomas. Biochimie 94(2): 487-493.
  • Shuralev E., Quinn P., Doyle M., Duignan A., Kwok H. F., Bezos J., Olwill S. A., Gormley E., Aranaz A., Good M., Davis W. C., Clarke J. and Whelan C. (2012) Application of the Enfer chemiluminescent multiplex ELISA system for the detection of Mycobacterium bovis infection in goats. Veterinary Microbiology 154(3-4):292-297.
  • Kwok H. F.*, Buick R. J.*, Kuehn D., Gormely J. A., Doherty D., Jaquin T. J., McClurg A., Ward C., Byrne T., Jaworski J., Leung K. L., Snoddy P., McAnally C., Burden R. E., Gray B., Lowry J., Sermadiras I., Gruszka N., Courtenay-Luck N., Kissenfennig A., Scott C. J., Johnston J. A. and Olwill S. A. (2011) Antibody targeting of Cathepsin S induces antibody-dependent cellular cytotoxicity. Molecular Cancer 10(1):147.
  • Whelan C., Shuralev E., Kwok H. F., Kenny K., Duignan A., Davis W. C. and Clarke J. (2011) Application of the Enferplex TB assay for the detection of tuberculosis positive cattle that were not detected by the SICTT. Journal of Veterinary Diagnostic Investigation 23(3):499-503.
  • Fry B. G., Winter K., Norman J. A., Roelants K., Nabuurs R. J. A., van Osch M. J. P., Teeuwisse W. M., van der Weerd L., McNaughtan J. E., Kwok H. F., Scheib H., Greisman L., Kochva E., Miller L. J., Gao F., Karas J., Scanlon D., Lin F., Kuruppu S., Shaw C., Wong L., Kuruppu S. and Hodgson W. C. (2010) Functional and structural diversification of Anguimorpha lizard venom system. Molecular & Cellular Proteomics 9(11):2369-2390.
  • Zhang Y., Wang L.,Zhou M., Zhou Z., Chen X., Chen T., Kwok H. F., Ivanyi C. and Shaw C. (2010) The structure of helokinestatin-5 and its biosynthetic precursor from Gila monster (Heloderma suspectum) venom: Evidence for helokinestatin antagonism of bradykinin-induced relaxation of rat tail artery smooth muscle. Peptides 31(8):1555-1561.
  • Kwok H. F.*, Scott C. J., Snoddy P., Buick R. J., Johnston J. A. and Olwill S. A. (2010) Profiling the humoral immune response of diagnostically sensitive mycobacterial (M. bovis) antigens in animal models. Research in Veterinary Science 89(1):41-47.
  • Whelan C., Whelan A. O., Shuralev E., Kwok H. F., Hewinson G., Clarke J. and Vordermeier H. M. (2010) Performance of the Enferplex TB assay in GB cattle and assessment of potential suitability as a DIVA test. Journal of Clinical Microbiology 17(5):813-817.
  • Kwok H. F.*, Ivanyi C., Morris A. and Shaw C. (2010) Review — Proteomic & Genomic studies on lizard venoms in the last decade. Proteomics Insights 3: 25-31.
  • Fry B.G., Roelants K., Winter K., Hodgson W. C., Griesman L., Kwok H. F., Scanlon D., Karas J., Shaw C., Wong L., Norman J. A. (2010) Novel venom proteins produced by differential domain-expression strategies in Beaded lizards and Gila monsters (genus Heloderma). Molecular Biology and Evolution 27(2): 395-407.

  • Kwok H. F.*, Gormley J. A., Scott C. J., Johnston J. A. and Olwill S. A. (2009) A Novel High-Throughput Technique for Identifying Monoclonal Antibodies Capable of Death Receptor Induced Apoptosis. Journal of Cell Death 2: 45-51.
  • Fry B. G., Teeuwisse W, Van Osch M. J. P., Scheib H, Winter K. L., Greisman L., Roelants K, Van der Weerd L., Clemente C. J., Giannakis E., Hodgson W. C., Luz S., Martelli P., Krishnasamy K., Kochva E., Kwok H. F., Scanlon D., Karas J., Citron D. M., Goldstein E. J. C., Mcnaughtan J. E. and Norman J. (2009) Central role for venom in predation by the Komodo Dragon and the giant extinct Megalania. PNAS 106(22): 8969-8974.
  • Whelan C., Shuralev E., O’Keeffe G., Hyland P., Kwok H. F., Snoddy P., Olwill S. A., Groll M., Watterson T., Call S., Costello E., Johnston J. A., Hamilton M .J., Davis W. C. and Clarke J. (2008) Multiplex immunoassay for the serological diagnosis of Mycobacterium bovis infected cattle. Clinical and Vaccine Immunology 15: 1834-1838.
  • Kwok H. F.* and Ivanyi C. (2008) Venom acquisition from helodermatid lizards. Herpetological Review 39(2): 179-181.
  • Kwok H. F.*, Chen T., Ivanyi C. and Shaw C. (2008) DNA in Amphibian and Reptile Venom Permits Access to Genomes Without Specimen Sacrifice. Genomics Insights 1: 17-24.
  • Kwok H. F.*, Chen T., O’Rourke M., Ivanyi C., Hirst D. and Shaw C. (2008) Helokinestatin: a novel bradykinin B2 receptor antagonist decapeptide from lizard venom. Peptides 29: 65-72.
  • Chen T., Kwok H. F., Ivanyi C. and Shaw C. (2006) Isolation and cloning of exendin precursor cDNAs from single samples of venom from the Mexican beaded lizard (Heloderma horridum) and the Gila monster (Heloderma suspectum). Toxicon 47(3): 288-295.
  • Chen T., Folan R., Kwok H. F., Bjourson A. J. and Shaw C. (2003) Isolation of scorpion (Androctonus amoreuxi) putative alpha neurotoxin and parallel cloning of their respective cDNAs from a single sample of venom. Regulatory Peptide 115(2): 115-121.
  • Chen T., Bjourson A. J., Orr D. F., Kwok H. F., Ping F., Ivanyi C. and Shaw C. (2002) Unmasking venom gland transcriptomes in reptile venoms. Analytical Biochemistry 311: 152-156.
Book Chapters:

  • Fry B. G., Roelants K., Jackson T. N. W., Takacs Z., Reeks T. and Kwok H. F.* (2015) Chapter 18 B-Type natriuretic peptides. In Bryan Fry (Ed.), Venomous Reptiles and Their Toxins (pp. 312-317). Oxford, UK: Oxford University Press.
  • Fry B. G., Roelants K., Jackson T. N. W., Takacs Z., Reeks T. and Kwok H. F.* (2015) Chapter 11 Exendin peptides. In Bryan Fry (Ed.), Venomous Reptiles and Their Toxins (pp. 247-254). Oxford, UK: Oxford University Press.

*corresponding author

Research Grants 
2017-2020 The Science and Technology Development Fund (FDCT) — Minister of Science and Technology of China (MOST), Investigation of the correlation between PD-L1 expression and KRAS signaling pathway and its potential clinical application.
2015-2018 The Science and Technology Development Fund (FDCT), Investigate the role of MCM10 in breast cancer progression & its potential as a therapeutic target.
2015-2018 University of Macau Multi-Year Research Grant, A model system for structural and functional convergence of venom peptides: unlock a new era in drug development.
2015–2018 University of Macau Multi-Year Research Grant, Osteopontin (OPN) expression as a prognostic indicator in colorectal cancer & its potential as a therapeutic target
2014-2016 University of Macau Start-Up Research Grant, Investigate novel regulator(s) for ADAM17 ectodomain shedding by cellular & proteomics approaches: Evaluation in biology and medicine.
2011-2016 Cancer Research UK Research Grant (with Prof Gillian Murphy), Development of human TACE (mouse & human cross-reactive) therapeutic antibody against cancer.
2007-2011 Invest Northern Ireland (NI) European Development Research Fund, Discovery, development & evaluation of the therapeutic efficacy of APO-1 antibody and human Cathepsin S antibody for the treatment of cancer.
2006-2009 InterTrade Ireland Innova Grant, TB diagnostic kit/assay development
2004-2007 UK Technology Strategy Board KTP Funding, Define the shortfalls in current protein production techniques, and to develop novel techniques to permit more efficient and scaled protein engineering, protein expression and protein purification
  1. Olwill S. A., Kwok H. F., Johnston J. A., Whelan C., Clarke J., Shuralev E. (2010) Diagnostic methods and kits – The identification of tuberculosis infection in animals such as badgers, cervids and wild boar. Patent WO 2010097625
  2. Olwill S. A., Buick R., Kwok H. F., Scott C., Ward C. (2010) Antibody Therapy – Described are methods of inhibiting angiogenesis, the methods comprising the simultaneous, sequential or separate administration of (i) an anti- Cathepsin S antibody molecule, and (ii) an anti-VEGF antibody molecule. Also described are anti-Cathepsin S humanized antibodies, pharmaceutical compositions and methods of treatment using such antibodies. Patent WO 2010094981
  3. Olwill S. A., Johnston J. A., Kwok H. F., Whelan C, Clarke J. (2009) Diagnostic method and kit – The invention relates to methods for diagnosis of tuberculosis comprising determining the presence or absence of, or an immune response to a group of antigens. Patent WO2009024822
  4. Olwill S. A., Buick R. J., Kwok H. F., Johnston J. A. (2006) Assays for diagnosis of tuberculosis and uses thereof – The identification of mycobacterial antigens which are highly immunogenic and which may be used in assays and methods for the diagnosis of tuberculosis. Patent WO2006117538
2014 Winner of Protein Discovery Summit Poster Presentation:
GTC’s 2nd Antibody & Protein Therapeutics Conference
2011-2014 CRUK Research Fellowship
2008 Winner of Knowledge Transfer Partnership (KTP) Regional Award
2004-2007 Knowledge Transfer Partnerships (KTP) Fellowship
2000-2003 Vice-Chancellor Research Scholarship
1999 University of Ulster Overseas student Bursary Award
Professional Activities
Society Membership:

  • Antibody Society
  • Biochemical Society
  • International Society on Toxinology
  • Institute of Biomedical Science
  • Chartered Management Institute
  • American Association for Cancer Research
Ad Hoc Reviewer of Journals:

  • Seminars in Cancer
  • Advances in Modern Oncology Research
  • BMC Urology
  • Breast Cancer Targets and Therapy
  • Biomedicine & Pharmacotherapy
  • British Journal of Medicine and Medical Research
  • Cancer Biomarkers
  • Cancer Biology & Medicine
  • Cancer Management & Research
  • Cancer Informatics
  • Cell Biology International
  • Current Pharmaceutical Biotechnology
  • Current Drug Targets
  • Current Protein & Peptide Science
  • Current Enzyme Inhibition
  • Cancer Biology & Treatment
  • Experimental and Therapeutic Medicine
  • Future Oncology
  • International Journal of Biological Sciences
  • International Journal of Nanomedicine
  • International Journal of Oncology
  • Journal of Cell Science & Therapy
  • Journal of Cellular and Molecular Medicine
  • Journal of Cancer
  • mAbs
  • Molecular Biology Reports
  • Molecular Medicine Reports
  • OncoTargets & Therapy
  • Oncology Reports
  • Oncology Letters
  • Oncotarget
  • PeerJ
  • PLoS One
  • PNAS
  • Peptides
  • Pharmacology & Therapeutics
  • Regulatory Peptide
  • Research in Veterinary Science
  • Scientific Reports
  • Tumor Biology
  • Toxicon
  • Theranostics
Reviewer of Book Chapter:

  • Bioactive Natural Products — Elsevier Science Publishers, Amsterdam
Invited External Examiners:

  • School of Pharmacy, Queen’s University Belfast, UK — PhD programme
  • Li Ka Shing Faculty of Medicine, University of Hong Kong — MMedSc programme
  • Faculty of Medicine, Nursing & Health Sciences, Monash University, Australia — PhD programme
Invited Editorial Service:

  • Editorial Board Member of Toxins (ISSN 2072-6651)
  • Guest Editor — Toxins (Special Issue: Venom and Toxins as Targeted Therapy)
  • Editorial Board Member of Advances in Modern Oncology Research (ISSN 2424-7855)
  • Editorial Board Member of ADMET and DMPK (ISSN 1848-7718)
Conference Presentations

  1. Kwok H. F. 3rd Antibody & Protein Therapeutics Conference 2014, Boston, USA. “Discovery and Development of Therapeutic TACE (ADAM17) Antibodies”.
  2. Li B., Xi X, Chen T., Shaw C. and Kwok H. F. 18th World Congress of the International Society on Toxinology 2015, Oxford, UK. “High-throughput approach for isolation and identification of novel peptides with anticancer activities from scorpion venoms”.
  3. Lin Y., Meng C., Lin W., Cheng G. and Kwok H. F. 3rd Macao Symposium on Biomedical Sciences 2016, Macau SAR. “Regulation of PD-L1 by KRAS and p53”.
  4. Yuen S.M., Ye J., Murphy G., Xie R. and Kwok H. F. 5th IAPC Meeting 2016 — Emerging Technologies in Drug Discovery and Development, Zhuhai, China. “Anti-Tumour Effects of a Human & Mouse Cross-Reactive’ Anti-TACE Antibody in a Pancreatic Cancer Model In Vivo”. (Invited keynote speaker)